Effect of pegylation on pharmaceuticals

By J. Harris, Robert B. Chess. Nature reviews. Drug discovery, 2003

3,236 citations recorded by the source corpus.

Subfields: Epidemiology, Hepatology, Oncology

View Paper: https://www.semanticscholar.org/paper/f2b71c67ad4d67b4987d9fb34dbb2437c0ae84ab

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

In Hepatology

In Oncology

Citations in the corpus

Superparamagnetic iron oxide nanoparticles (SPIONs): development, surface modification and applications in chemotherapy. (2011, background): “for treatment of neurological or psychiatric disorders) to the brain [281].”
PEGylation of therapeutic proteins (2010, background): “In general, low immunogenicity of PEG and relatively low dosages of PEG-conjugates reduce the risk for an immunogenic response significantly [23, 35–38].”
Polymers for Drug Delivery Systems (2010, background): “The first-to-market products, with their brand name and year of approval in parentheses, include PEG-L-asparaginase (Oncaspar, 1994) for leukemia, styrene maleic anhydride-neocarzinostatin (Zinostatin Stimalmer, 1993) for hepatocellular carcinoma, PEG-granulocyte colony-stimulating factor (Neulasta,”
In situ Forming Injectable Hydrogels for Drug Delivery and Wound Repair (2018, neutral): “Therapeutic molecules that are unstable in vivo due to susceptibility to enzymatic degradation or rapid clearance by the kidneys must be delivered at concentrations far higher than required for therapeutic effect [39].”
Design and fabrication of magnetic nanoparticles for targeted drug delivery and imaging (2009, background): “Specifically, hydrophobic and charged NPs have short circulation times due to adsorption of plasma proteins (opsonization) which can lead to recognition by the reticuloendothelial system (RES), followed by removal from circulation [41].”
Combination therapy: opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines. (2009, background): “Some systems, such as liposomes [1], microparticles [2] and PEGylated proteins [3,4], are well established, others, such as polymer–drug conjugates are expected to reach the market in the near future [5].”
The journey of a drug-carrier in the body: an anatomo-physiological perspective. (2012, background): “It is not the objective of this review to cover surface modification strategies, (see refs, [33,35,67,68] for more information on this topic) but PEGylation still remains today the gold standard to impart CDCs with long circulation times [69,70].”
Computationally Guided Photothermal Tumor Therapy Using Long-Circulating Gold Nanorod Antennas (2009, methodology): “We chose a PEG polymer coating due to the widespread clinical use of variable-length PEG polymers for extending the circulation time of protein therapeutics (23, 24) and for nanoparticle formulations, such as the drug-loaded liposomes Doxil.”